EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...
European watchdog partially approves new Alzheimer's drug
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...
Pharmaceutical Technology35m
EMA rethinks stance, committee now recommends Leqembi for Alzheimer’s disease
The EMA’s Committee for Medicinal Products for Human Use has issued a positive recommendation for Eisai and Biogen’s Leqembi ...
WKBW51m
Alzheimer's Awareness Month: Grand Island couple shares experience with disease
November is Alzheimer's Awareness Month and 7 News met Grand Island couple Tom and Michele Drabik, who shared their experience with the disease.
Krone4m
EU: First green light for Alzheimer’s therapy
The European Medicines Agency (EMA) has given the green light for the first Alzheimer's therapy in the EU that targets the ...
New insight into brain stability: the key role of NMDA receptors
Researchers at Tel Aviv University have made a fundamental discovery: the NMDA receptor (NMDAR)—long studied primarily for ...
University of Waterloo24m
Nine Waterloo researchers awarded $7.5 million
Nine researchers at the University of Waterloo have been awarded $8.9 million in funding to support their research as part of the illustrious Canada Research Chairs (CRC) program. Each year, the CRC ...